340B providers are sighing relief after U.S. Sen. John Thune (S.D.), a staunch 340B provider ally and the Senate’s No. 2 Republican, announced over the weekend he will seek re-election in November.
Thune announced that he was running on
…
Category: Legislative
In his monthly column for Omnicell’s blog, 340B Report Publisher and Chief Executive Officer Ted Slafsky makes three big predictions for the 340B program for 2022. They focus on:
- the U.S. Supreme Court case on Medicare reimbursement to 340B
South Dakota U.S. Sen. John Thune, the second-ranking Senate Republican and a long-time 340B covered entity ally, might not run for re-election in 2022, two news organizations report. It would be a significant blow to 340B providers who have counted
…
U.S. Sen. Joe Manchin (D-W.Va.) has suggested that the U.S. Department of Veterans Affairs (VA) be empowered to negotiate drug prices on behalf of Medicare, an initiative that may impact the 340B program if it should come to fruition.
Manchin
…
West Virginia U.S. Sen. Joe Manchin’s rejection Sunday of his fellow Democrats’ Build Back Better (BBB) policy agenda left its drug pricing section dead in the water.
Manchin said of the BBA bill on Dec. 19, “I cannot vote to
…
The U.S. House Oversight and Reform Committee issued a blistering report late last week accusing brand pharmaceutical manufacturers of systematically jacking up prices on their drugs in the United States.
Pharmaceutical Research and Manufacturers of America (PhRMA) called it a
…
The U.S. Senate Finance Committee’s latest drug pricing legislation includes language, not seen before in earlier House and Senate versions, about denying 340B covered entities’ access to government-negotiated lower prices on drugs covered under Medicare.
The committee released the
The Democratic-led U.S. House Oversight and Reform Committee is holding a hearing this Thursday to review the findings of its nearly three-year investigation into drug industry pricing and business practices.
The Dec. 9 hearing starts at 10:30 a.m. Eastern. It’s
…
U.S. Rep. Peter Welch (D-Vt.), who has backed 340B covered entities in several policy battles, is running to succeed his fellow Democrat Patrick Leahy in the U.S. Senate.
Senate President Pro Tempore Leahy, 81, announced on Nov. 15 that he
…